Rockwell Medical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Rockwell Medical reported 3rd quarter 2026 net sales of $19.1 million, up 20% over the same period in 2025, driven primarily by sales to new customers in the West and larger purchasing volumes from existing customers, particularly the top 5 dialysis providers in the U.S.
- For the 9 months ended September 30th, 2026, net sales were $54.2 million, up 7% over the same period in 2025.
- 3rd quarter gross profit was $3.1 million, up 37% year over year, and gross margin was 16%, compared with 14% in the same period in 2025; 9-month gross profit was $9.3 million, up 18%, and gross margin was 17%, compared with 15% in 2025.
- 3rd quarter net loss was $2.3 million, including approximately $800,000 in acquisition-related expenses, compared with $1.8 million in the same period in 2025; 9-month net loss was $5.1 million, compared with $4.8 million in 2025.
- Adjusted EBITDA was negative $300,000 for the 3rd quarter 2026, compared with $50,000 in the same period in 2025, and negative $700,000 for the 9-month period, compared with negative $600,000 in 2025.
- Cash, cash equivalents, and investments available for sale were $22.5 million at September 30th, 2026, down from $24.8 million at June 30th, 2026, primarily due to normal increases in accounts receivable and prepaid expenses and equipment purchases to automate production lines.
- The company serves approximately 300 customers and supplies products to more than 30 international markets through third-party distributors.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to Rockwell Medical's third quarter 2026 results conference call and webcast. Please note, this event is being recorded. At this time, I would like to turn the conference call over to Laura Guerrant-Oiye, Rockwell Medical's newly appointed Executive Director of Investor Relations.
Laura, please go ahead. Good morning, everyone, and thank you for joining us for this update on Rockwell Medical.
I am thrilled to be joining you today as Rockwell Medical's new Executive Director of Investor Relations. I look forward to working closely with our investment community and partnering with you moving forward. Joining me on today's conference call are Dr. Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's Chief Financial Officer. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC.
Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's quarterly report on Form 10-Q for the three months ended September 30, 2026, was filed prior to this call. The reconciliation of non-GAAP measures we discuss on today's call can be found in today's press release. Our Form 10-Q and other reports filed with the SEC, along with today's press release and a replay of today's conference call, can be found on Rockwell Medical's website under the Investor section.
With that, I will turn the call over to Rockwell Medical's President and CEO, Dr. Mark Strobeck.
Mark? Thank you, Laura, and good morning, everyone.
Thank you for joining us today for Rockwell Medical's third quarter 2026 earnings conference call and webcast. We are excited to welcome Laura, who recently joined us as our new Executive Director of Investor Relations. Laura brings to Rockwell more than 30 years experience in investor relations and capital markets, especially within the healthcare sector. Laura now leads our investor relations function and will serve as a key liaison between Rockwell Medical and our shareholders, analysts, prospective investors, and the broader investment community. This morning, our remarks are organized around three key topics. One, the continued execution of our plan for our core hemodialysis business. Two, the future impact of our pending acquisition of Vantive's global hemodialysis business. Three, the potential opportunity inherent in the new U.S. Department of Health and Human Services Kidney Care National Plan.
During the third quarter of 2026, we continued to grow our core hemodialysis concentrates business through customer acquisition, geographic expansion, enhanced customer retention, and disciplined pricing. This resulted in net sales of $19.1 million for the third quarter 2026, which represented a 20% increase over the same period in 2025. During his remarks, Jesse will review our third quarter 2026 financial results in greater detail. The hemodialysis market continues to evolve as several industry participants adjust their product portfolios and operations. Additionally, there have been publicly disclosed FDA recalls involving certain dialysis products manufactured by other suppliers. Against that backdrop, we continue to focus on being a reliable supplier and delivering high-quality products. We believe this focus on quality and reliability continue to support our customer relationships and net sales growth. It's how we win business and how we keep it.
During the third quarter, we saw increased demand from our existing customers, including the top five major dialysis providers in the United States. As a result, we maintained solid upward momentum across our business, driven by robust market demand and disciplined execution. Today, we serve approximately 300 customers while also supplying products to more than 30 international markets through third-party distributors. We continue to have productive discussions with some of our largest customers regarding opportunities to expand our existing relationships and increase product volumes. We will provide updates when appropriate. The second topic we would like to discuss is the Vantive acquisition. Last week, we announced that we entered into an Equity and Asset Purchase Agreement with Vantive Limited, under which we will acquire Vantive's hemodialysis concentrates, hemodialysis machines, water treatment systems, and related consumables and technical services business.
In addition, we will acquire Vantive's state-of-the-art 1 million square foot manufacturing campus in Medolla, Italy. This acquisition will broaden our portfolio within the hemodialysis sector beyond concentrates and will also add established international customer relationships, distribution capabilities, technical expertise, and a global manufacturing footprint. Together, these capabilities will expand the scale, scope, and strategic reach of Rockwell Medical, creating a more diversified global hemodialysis platform with the ability to serve customers across a broad range of products and geographies. This acquisition is transformational for us. By bringing these two businesses together, we have the opportunity to form one of the world's leading hemodialysis medical device manufacturers and suppliers with a scale and global presence that would otherwise take years to build organically. Upon closing, we estimate that the combined business will bring together a global workforce of more than 1,000 employees across more than 36 countries.
Based on the current revenue profile of the two businesses, we expect the combined business to generate annual revenue between $400 million and $450 million, approximately 90% of which is expected to be reoccurring. Between signing and closing, which remains subject to customary closing conditions and regulatory approvals, and is currently expected to occur in mid-2027, our priorities are clear. The transaction contemplates a Transition Services Agreement and manufacturing and supply agreement with Vantive to support the orderly transition of the business, especially with respect to employees, customers, systems, processes, manufacturing, product registrations, and distribution. We plan to work closely with Vantive and focus on continuity of supply, along with support for customers, patients, and employees throughout the transition. At the same time, we will be preparing Rockwell Medical to operate as a larger, more global organization following closing.
We look forward to keeping you updated as we continue to make progress. Lastly, I want to touch on the Kidney Care National Plan announced last month by HHS. The plan is built around three priorities. One, preventing kidney failure. Two, improving dialysis care and expanding patient choice. And three, reforming transplantation. Specifically citing the announcement, the plan identifies where federal action can improve kidney care across the entire spectrum of kidney disease, eliminate regulatory barriers to support innovation and a well-functioning kidney market, and deliver greater choice and superior outcomes to patients in the U.S. For Rockwell, the most compelling aspect of this announcement is the plan's continued focus on restoring competition in dialysis care.
HHS describes a market weakened by decades of regulation that too often protects incumbents rather than patients, and the plan sets out to remove barriers that inhibit competition and innovation, and to reduce barriers to entry for new providers and treatments. The plan emphasizes innovation, patient choice, and access to dialysis care, including home-based care. We view this as a positive step for both patients and providers. Additionally, we believe this presents a long-term opportunity for Rockwell Medical as the care model evolves, because our products support hemodialysis wherever patients receive care, whether in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Our role within this ecosystem is straightforward: be where the patients are, whether that is at home or in the clinic.
We provide reliable service, high-quality products, and continuity of supply to the customers and patients who depend on us for our life-saving hemodialysis products so that patients have more choices in how and where they receive care. Our core concentrates business, together with the broader capabilities we expect to add through the Vantive transaction, present an opportunity to strengthen our ability to fulfill that role across a larger and more diverse hemodialysis sector. This initiative leverages our core strengths, and we fully support HHS in the endeavor to revitalize American kidney care. With that, I'll now turn the call over to Jesse.
Thank you, and good morning, everyone. Net sales for the three months ended September 30, 2026, were $19.1 million, representing a 20% increase over net sales for the same period in 2025. The increase was primarily driven by sales to new customers in the West and larger purchasing volumes from existing customers, particularly the top five dialysis providers in the U.S., all of which are current Rockwell Medical customers. For the nine months ended September 30, 2026, net sales were $54.2 million, which represents a 7% increase over net sales for the same period in 2025. Gross profit for the third quarter was $3.1 million, which represents a 37% increase over gross profit for the same period in 2025. Gross profit for the nine months ended September 30, 2026, was $9.3 million, which represents an 18% increase over gross profit for the same period in 2025.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
